GlassScriptPhysician profile
Frank Golden
NPI 1033704051
$10,263.14
in general payments reported to CMS, 2019-2025
30 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,031 · 2022: $2,903 · 2023: $2,090 · 2024: $1,392 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,143 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,142.52 |
| Education | $186.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,770.14 | 2021-2025 | |
| Alkermes, INC. | $1,176.44 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,094.94 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,052.78 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $796.82 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $667.29 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $616.33 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $492.31 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $491.21 | 2021-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $345.19 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $314.91 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $285.67 | 2021-2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $199.98 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $149.53 | 2023-2024 | Auvelity |
| Corium, LLC | $136.07 | 2022-2024 | Azstarys |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $115.06 | 2022-2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $104.09 | 2021-2023 | Belsomra |
| Noven Therapeutics, LLC | $84.30 | 2021-2022 | |
| Eisai INC. | $64.43 | 2021-2022 | |
| Indivior INC. | $50.47 | 2021-2022 | |
| Braeburn INC. | $42.05 | 2025 | Brixadi |
| Bausch Health US, LLC | $40.02 | 2021-2022 | |
| Biogen, INC. | $37.02 | 2022 | |
| Tris Pharma INC | $37.01 | 2025 | Dyanavel Xr |
| Noven Pharmaceuticals, INC. | $23.02 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.29 | 2022 | |
| Owp Pharmaceuticals, INC. | $16.41 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.70 | 2023 | Quviviq |
| Alfasigma USA, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.